59961-15-8Relevant articles and documents
METHODS OF TREATING NEURODEGENERATIVE DISEASES
-
Paragraph 0194, (2020/03/23)
Described herein are methods of treating or preventing an ASK1 or DYRK1A associated disease, disorder, or condition comprising administering to a subject in need thereof a dual inhibitor of ASK1 and DYRK1A; including administering pharmaceutically acceptable salts and solvates thereof.
New tetracyclic compound
-
Paragraph 0393-0397, (2019/11/14)
The invention relates to a new tetracyclic compound. The tetracyclic compound has a structure shown in the formula (III) and can be used as a bromine domain and additional terminal (BET) inhibitor. The invention further relates to synthesis and application of the compounds in disease treatment. More specifically, the invention relates to a fused heterocyclic derivative used as a BET inhibitor, a method for the preparation of these compounds, and a disease and symptom treatment method conductive to inhibition of one or more BET bromine domains.
HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF
-
Paragraph 0512, (2016/05/02)
The present invention relates to imidazo pyridine compounds, and pharmaceutically acceptable compositions thereof, useful as BTK inhibitors.